RECRUITING

Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this intervention study is to learn about how weight loss impacts molecular signaling of intermuscular adipose tissue (IMAT) in individuals with obesity. The main question it aims to answer is how inflammatory molecules secreted by IMAT promote muscle insulin resistance and inflammation, and how these same molecules are diminished after weight loss. Following screening visits involving body composition measures, blood testing, strength testing, and a thigh muscle biopsy, participants will go through a 12-week dietary intervention for weight loss. After 12 weeks, this will be followed by the same testing and biopsies that were completed before the intervention. Researchers will then compare outcomes of individuals who lost weight to individuals who did not lose weight.

Official Title

Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling

Quick Facts

Study Start:2024-01-01
Study Completion:2029-12-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06129110

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 70 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Generally healthy men and women aged 18-70
  2. * BMI between 30-40
  3. * Less than 1 hour of exercise per week
  4. * Women:
  5. 1. may be pre or post menopausal
  1. * Type 1 or Type 2 diabetes
  2. * Thyroid disease
  3. * History of lung disease
  4. * Active use of nicotine
  5. * Severe plasma lipid disorders
  6. * Taking hormone replacement drugs, blood thinners, or thiazoladinediones
  7. * Women:
  8. 1. Currently going through menopause or peri-menopause
  9. 2. Pregnant or breastfeeding
  10. 3. History of Polycystic Ovary Syndrome

Contacts and Locations

Study Contact

Bryan Bergman, PhD
CONTACT
3037243919
bryan.bergman@cuanschutz.edu
Sophia Bowen
CONTACT
3037240487
sophia.bowen@cuanschutz.edu

Study Locations (Sites)

University of Colorado Anschutz
Aurora, Colorado, 80045
United States

Collaborators and Investigators

Sponsor: University of Colorado, Denver

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-01-01
Study Completion Date2029-12-01

Study Record Updates

Study Start Date2024-01-01
Study Completion Date2029-12-01

Terms related to this study

Keywords Provided by Researchers

  • IMAT
  • Intermuscular Adipose Tissue
  • Weight Loss
  • Diet

Additional Relevant MeSH Terms

  • Obesity
  • Insulin Sensitivity
  • Muscle Weakness
  • Adiposity
  • Insulin Resistance